April 29, 2008 / 9:13 PM / in 10 years

UPDATE 1-BioMarin posts Q1 profit; raises 2008 revenue view

(Recasts; adds details, share movement)

April 29 (Reuters) - Biotechnology company BioMarin Pharmaceutical Inc (BMRN.O) reported a quarterly profit that beat market estimates, helped by strong sales of two of its enzyme replacement therapies, and raised its full-year revenue outlook.

The company posted first-quarter earnings of $1.7 million, or 2 cents a share, compared with a net loss of $9.3 million, or 10 cents a share, a year earlier.

Revenue surged 165 percent to $60.4 million.

Analysts on average were expecting the company to report a loss of 4 cents a share on revenue of $55.7 million, according to Reuters Estimates.

Sales of its enzyme replacement therapy (ERT) Naglazyme were $27.7 million, up from $18.4 million in the year-ago quarter. Net sales of BioMarin’s other ERT, Aldurazyme, rose about 37 percent to $36.8 million .

    The company based in Novato, California, said it expects 2008 earnings of $28 million to $40 million, on revenue of $271 million to $316 million.

    It had previously expected net income of $20 million to $40 million on revenue of $255 million to $306 million. Analysts were expecting earnings of 41 cents a share, on revenue of $302.6 million for the period.

    Shares of the company were trading at $35.00 after the bell. The stock closed at $33.77 Tuesday on Nasdaq. (Reporting by Aradhana Aravindan in Bangalore; Editing by Deepak Kannan)

    0 : 0
    • narrow-browser-and-phone
    • medium-browser-and-portrait-tablet
    • landscape-tablet
    • medium-wide-browser
    • wide-browser-and-larger
    • medium-browser-and-landscape-tablet
    • medium-wide-browser-and-larger
    • above-phone
    • portrait-tablet-and-above
    • above-portrait-tablet
    • landscape-tablet-and-above
    • landscape-tablet-and-medium-wide-browser
    • portrait-tablet-and-below
    • landscape-tablet-and-below